Literature DB >> 16110140

Signaling molecules and cytokine production in T cells of patients with B-cell chronic lymphocytic leukemia (B-CLL): comparison of indolent and progressive disease.

Shahryar Kiaii1, Aniruddha Choudhury, Fariba Mozaffari, Eva Kimby, Anders Osterborg, Håkan Mellstedt.   

Abstract

T-cell dysfunction in B-CLL patients might be attributed to altered expression of components of the TCR/CD3 complex and associated intracellular tyrosine kinases. Four-color flow cytometry was applied to the expression of these molecules as well as the T-cell regulatory cytokines (IFN-gamma and IL-4) in B-CLL patients with indolent and progressive disease. Intracellular levels [mean fluorescent intensity (MFI)] of IFN-gamma and IL-4 in both CD4 and CD8 T cells of both patient groups were significantly higher than in healthy donors. Absolute number of IL-4 producing CD4 T cells in patients with indolent was significantly higher than in healthy donors. The expression level (MFI) of the CD3-zeta chain was higher in patients than in normal donors as well as ZAP-70 in patients with indolent disease as compared to healthy donors and progressive patients. No significant difference was noted in the expression of p56lck, p59fyn, and PI3-kinase between healthy donors and patients or between the patient subgroups. The results indicate multiple T-cell abnormalities especially in indolent-stage B-CLL suggesting a state of chronic and aberrant activation. This information might be of significance when studying the immunobiology of B-CLL as well as developing new therapeutic approaches.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16110140     DOI: 10.1385/MO:22:3:291

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  42 in total

Review 1.  Chronic lymphocytic leukemia.

Authors:  T J Kipps
Journal:  Curr Opin Hematol       Date:  2000-07       Impact factor: 3.284

2.  The protooncogene TCL1 is an Akt kinase coactivator.

Authors:  J Laine; G Künstle; T Obata; M Sha; M Noguchi
Journal:  Mol Cell       Date:  2000-08       Impact factor: 17.970

3.  T cells and CD45R expression in B-chronic lymphocytic leukemia.

Authors:  P G Briggs; N Kraft; R C Atkins
Journal:  Leuk Res       Date:  1990       Impact factor: 3.156

4.  Clonal expansion within the CD4+CD57+ and CD8+CD57+ T cell subsets in chronic lymphocytic leukemia.

Authors:  D Serrano; J Monteiro; S L Allen; J Kolitz; P Schulman; S M Lichtman; A Buchbinder; V P Vinciguerra; N Chiorazzi; P K Gregersen
Journal:  J Immunol       Date:  1997-02-01       Impact factor: 5.422

5.  Differences in blood T and NK cell populations between chronic lymphocytic leukemia of B cell type (B-CLL) and monoclonal B-lymphocytosis of undetermined significance (B-MLUS).

Authors:  E Kimby; H Mellstedt; B Nilsson; M Björkholm; G Holm
Journal:  Leukemia       Date:  1989-07       Impact factor: 11.528

Review 6.  Impairments in immune cell function in B cell chronic lymphocytic leukemia.

Authors:  M M Bartik; D Welker; N E Kay
Journal:  Semin Oncol       Date:  1998-02       Impact factor: 4.929

7.  Lymphocyte subpopulations in chronic lymphocytic leukemia. Characterization by cell surface markers, cytotoxic activity, and mitogenic stimulation.

Authors:  H Mellstedt; D Pettersson
Journal:  Scand J Immunol       Date:  1974       Impact factor: 3.487

8.  Imbalance of T cell subpopulations in patients with chronic lymphocytic leukaemia of the B cell type.

Authors:  F Herrmann; A Lochner; H Philippen; B Jauer; H Rühl
Journal:  Clin Exp Immunol       Date:  1982-07       Impact factor: 4.330

9.  Interleukin-4 inhibits both paracrine and autocrine tumor necrosis factor-alpha-induced proliferation of B chronic lymphocytic leukemia cells.

Authors:  C van Kooten; I Rensink; L Aarden; R van Oers
Journal:  Blood       Date:  1992-09-01       Impact factor: 22.113

10.  Effect of anti-APO1 on spontaneous apoptosis of B cells in chronic lymphocytic leukaemia: the role of bcl-2 and interleukin 4.

Authors:  T Mainou-Fowler; V A Craig; A J Copplestone; M D Hamon; A G Prentice
Journal:  Leuk Lymphoma       Date:  1995-10
View more
  5 in total

Review 1.  New treatments for chronic lymphocytic leukemia.

Authors:  Asher A Chanan-Khan
Journal:  Curr Oncol Rep       Date:  2007-09       Impact factor: 5.075

2.  Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response.

Authors:  Asher A Chanan-Khan; Kasyapa Chitta; Noreen Ersing; Aneel Paulus; Aisha Masood; Taimur Sher; Abhisek Swaika; Paul K Wallace; Terry L Mashtare; Greg Wilding; Kelvin Lee; Myron S Czuczman; Ivan Borrello; Naveen Bangia
Journal:  Br J Haematol       Date:  2011-10-20       Impact factor: 6.998

3.  Treatment with lenalidomide modulates T-cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia.

Authors:  Bang-Ning Lee; Hui Gao; Evan N Cohen; Xavier Badoux; William G Wierda; Zeev Estrov; Stefan H Faderl; Michael J Keating; Alessandra Ferrajoli; James M Reuben
Journal:  Cancer       Date:  2011-02-24       Impact factor: 6.860

4.  IFN gamma gene polymorphism may contribute to the susceptibility to CLL.

Authors:  Iwona Urbanowicz; Grzegorz Mazur; Jolanta Stacherzak-Pawlik; Katarzyna Bogunia-Kubik; Tomasz Wróbel; Mieczysław Woźniak; Kazimierz Kuliczkowski
Journal:  Pathol Oncol Res       Date:  2009-09-15       Impact factor: 3.201

5.  Molecular action of lenalidomide in lymphocytes and hematologic malignancies.

Authors:  Jessica M McDaniel; Javier Pinilla-Ibarz; P K Epling-Burnette
Journal:  Adv Hematol       Date:  2012-07-24
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.